InvestorsHub Logo
Followers 59
Posts 7440
Boards Moderated 0
Alias Born 10/20/2014

Re: retinadoc post# 413046

Wednesday, 07/26/2023 7:49:55 AM

Wednesday, July 26, 2023 7:49:55 AM

Post# of 430139
Agreed! As we both understand Vascepa should (and still could) be a multi-billion
dollar drug even without the US. The problem that I see is that it is unlikely to happen
without BP having ownership. If Alex Denner can demonstrate to BP that they could
get Vascepa sales to the point of over $2 billion a year in revenues then they would
be justified in expecting a BO of $7-$9 billion. What bothers me is that what I see
as potentially massive new uses of Vascepa for Cancer and Alzheimer's disease
do not really seem to be on the radar screen. (I wish I had Alex Denner's thoughts
about these two prospective indications for Vascepa.) Of course, the CVD potential
by itself should justify a double digit BO price for AMRN. So pathetically sad that
a very safe and affordable medication that could literally benefit hundreds of
millions of people throughout the world cannot even muster a million users!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News